Solstice Biologics expands management team following achievement of technology milestones

Appoints Lou Tartaglia as President and CEO, while John Borgeson joins as CFO

Solstice Biologics, a US company focused on the targeting and delivery of nucleic acid therapeutics, says Lou Tartaglia has joined the company as President and Chief Executive. In addition, John Borgeson has been appointed as Chief Financial Officer.

The expansion of the leadership team follows the achievement of internal technology milestones that further enable RNA molecules to cross membranes of multiple cell types, a problem that has been a bottleneck in delivering on the therapeutic potential of RNA interference (RNAi) and microRNA outside the liver.

Solstice, founded in 2012, is funded by venBio and Aeris Capital.

Prior to joining Solstice, Tartaglia was a Partner at Third Rock Ventures. Before this, he was SVP and a General Manager of GeneLogic, and prior to that, he was Vice President of New Ventures at Millennium Pharmaceuticals, and also Vice President of Metabolic Diseases. He also worked at Genentech on tumour necrosis factor receptors.

Borgeson joins as Chief Financial Officer after serving as a financial advisor to Solstice since its inception. He spent 20 years at Pfizer, most recently as Vice President, Finance for the company's Biotherapeutic and Bioinnovation Centre.

Since leaving Pfizer in 2010, Borgeson has helped oversee finance for a variety of private companies, including venBio portfolio companies Labrys Biologics (recently acquired by Teva Pharmaceuticals) and Heart Metabolics.

You may also like

Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Subscribe now